Lower radiation for nose cancer after immunotherapy and chemo
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether giving a lower dose of radiation to the main tumor is safe and effective for people with nasopharyngeal cancer (a type of nose/throat cancer) who first receive a combination of immunotherapy (toripalimab) and chemotherapy. It aims to reduce side effects while still controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal cancer and have not yet started any cancer treatment.
- You are between 18 and 70 years old.
- Your cancer is stage II or III, but not the specific subtype T2N0M0.
- You are in generally good health (able to do daily activities without help, with normal blood counts and kidney/liver function).
- You do not have active autoimmune disease, hepatitis B or C, HIV, or other cancers within the past 5 years (except some minor skin or thyroid cancers).
- You are not pregnant or breastfeeding, and you have not taken high-dose steroids or live vaccines recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
This trial tests if lowering the radiation dose and area for the neck can be as effective as standard treatment for nasopharyngeal cancer. It aims to reduce side effects while still controlling the disease.
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.